Zacks Investment Research
18 Jun 2026, 17:50 UTC · 2h ago
FDA Accepts Roche's Filing for Lunsumio VELO-Polivy in LBCL
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
18 Jun 2026, 17:50 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA has accepted Roche's supplemental biologics license application (sBLA) for a subcutaneous formulation of Lunsumio in combination with Polivy for relapsed or refractory large B-cell lymphoma. — FDA acceptance is a critical regulatory milestone that moves a potential new revenue stream closer to commercialization.
+0.40Phase III SUNMO study data showed that the Lunsumio-Polivy combination reduced the risk of disease progression or death by 59% compared to the R-GemOx regimen. — Strong clinical efficacy data increases the probability of final FDA approval and future market adoption.
+0.30The FDA has set a target action date for the decision on the sBLA for February 9, 2027. — Provides a definitive timeline for the catalyst, though the date is distant enough to limit immediate price volatility.
+0.10Which stocks this story touches
Continue reading
6 related stories
Search tags
The FDA accepted a supplemental biologics license application for its drug Lunsumio VELO, showing strong phase III study results.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
16h ago
